-+ 0.00%
-+ 0.00%
-+ 0.00%

ALK expands strategic tablet supply partnership with Catalent

Barchart·09/30/2026 08:03:00
Listen to the news

Inside Information

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that it has expanded its long-standing contract manufacturing partnership with Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide. Establishing long-term supply robustness is a strategic priority for ALK, and the expanded agreement secures ALK long-term access to Catalent's Zydis® technology for all its allergen products, including potential future tablets for peanut and tree nut allergies.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.